This Plain Language Summary of Publication article (PLSP) from Future Oncology describes TROPiCS-04, a large study comparing sacituzumab govitecan (TRODELVY®) to standard chemotherapy in patients with advanced urothelial cancer that had progressed after platinum-based chemotherapy and immunotherapy. The antibody-drug conjugate, already approved for certain breast cancers, was tested to determine if it could help patients with treatment-resistant urothelial cancer live longer than those receiving conventional chemotherapy options.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial’ and was published in Annals of Oncology.

Visit ESMO using the link to read the original article.